{
    "nctId": "NCT00378313",
    "briefTitle": "A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer",
    "officialTitle": "A Phase 2 Study of Neoadjuvant Chemotherapy With Gemcitabine, Epirubicin and Paclitaxel (Taxol)[GET] in Locally Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Breast Cancer, Locally Advanced",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 76,
    "primaryOutcomeMeasure": "To determine the pathological response rate in tumors of patients with locally advanced breast cancer who receive 4 to 6 cycles of GET chemotherapy",
    "eligibilityCriteria": "Inclusion criteria:\n\n* Females only\n* Consent for the collection of biopsy tissue in RNAlater solution\n* Biopsy specimens that were obtained by core biopsy or incisional biopsy and placed in RNAlater solution\n* Breast cancer that is:\n\n  * unilateral\n  * diagnosed histologically as invasive breast cancer without evidence of metastatic disease (except for stage IV with positive supraclavicular nodes only)\n  * stage IIB, IIIA (T0-3N2), IIIB (T4N0-3 or T0-3N3), or IV (by involvement of positive supraclavicular nodes only). (Patients with clinical evidence of inflammatory breast cancer or superficial lesions must have a measurable mass in the breast or lymph nodes.)\n  * measurable by physical exam, mammography, sonogram, CT scan, MRI, or x-ray\n* Evidence of adequate organ function (liver, bone marrow, kidney)\n* Ability to perform an adequate level of physical activity (Zubrod scale 0, 1, or 2)\n* Life expectancy of at least 10 years\n* Childbearing potential terminated by surgery, radiation, or menopause, or attenuated by use of an effective non-hormonal, barrier contraceptive method\n* Disease-free from prior nonbreast malignancies for at least 5 years before entry\n* Adequate cardiac function( measured by baseline LVEF on MUGA or echocardiogram greater than or equal to the institution's lower limit of normal)\n\nExclusion criteria:\n\n* Male\n* Hormonal birth control\n* The use of hormonal agents or raloxifene\n* Active infection\n* Pregnancy or breastfeeding\n* Bilateral malignancy or a mass in the opposite breast suspicious for malignancy, unless there is biopsy proof that the mass is not malignant\n* Previous therapy for breast cancer\n* Nonmalignant systemic disease that would keep the patient from being given the treatment or would prevent long-term follow-up\n* Active cardiac disease that would preclude the use of epirubicin and/or Taxol\n* Significant abnormal peripheral nerve disease (greater than or equal to Grade 2)\n* Any prior anthracycline or taxane-containing chemotherapy\n* Use of any investigational agent within one month before enrollment\n* Excisional biopsy of the breast",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}